{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:50:28Z","timestamp":1740178228050,"version":"3.37.3"},"reference-count":38,"publisher":"American Society of Hematology","issue":"13","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunoglobulin light-chain (AL) amyloidosis is characterized by the deposition of misfolded monoclonal free light chains, with cardiac complications accounting for patient mortality. Clonal hematopoiesis of indeterminate potential (CHIP) has been associated with worse cardiovascular outcomes in the general population. Its significance in AL amyloidosis remains unclear. We collected clinical information and outcome data on 76 patients with a diagnosis of AL amyloidosis who underwent deep targeted sequencing for myeloid neoplasia\u2013associated mutations between April 2018 and August 2023. Variant allele frequency was set at 2% to call CHIP-associated mutations. CHIP mutations were present in patients with AL amyloidosis at a higher frequency compared with age-matched control individuals. Sixteen patients (21%) had at least 1 CHIP mutation. DNMT3A was the most frequent mutation (7\/16; 44%). Compared with patients without CHIP, patients with CHIP had a higher prevalence of t(11;14) translocation (69% vs 25%, respectively; P\u00a0= .004). Furthermore, among patients with renal involvement, those with CHIP had a lower Palladini renal stage (P\u00a0= .001). At a median follow-up of 32.5\u00a0months, the presence of CHIP was not associated with worse overall survival or major organ dysfunction progression-free survival. Larger studies and longer follow-up are needed to better define the impact of CHIP in patients with AL amyloidosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012840","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T20:19:27Z","timestamp":1713903567000},"page":"3427-3436","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Clonal hematopoiesis of indeterminate potential in patients with immunoglobulin light-chain AL amyloidosis"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7764-4336","authenticated-orcid":false,"given":"Paolo","family":"Lopedote","sequence":"first","affiliation":[{"name":"1Department of Medicine, St. Elizabeth\u2019s Medical Center, Boston University, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-1473","authenticated-orcid":false,"given":"Benjamin","family":"Evans","sequence":"additional","affiliation":[{"name":"2Amyloidosis Program, Brigham and Women\u2019s Hospital, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Marchetti","sequence":"additional","affiliation":[{"name":"4Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianzeng","family":"Chen","sequence":"additional","affiliation":[{"name":"2Amyloidosis Program, Brigham and Women\u2019s Hospital, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0964-0237","authenticated-orcid":false,"given":"Maria","family":"Moscvin","sequence":"additional","affiliation":[{"name":"2Amyloidosis Program, Brigham and Women\u2019s Hospital, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Boullt","sequence":"additional","affiliation":[{"name":"2Amyloidosis Program, Brigham and Women\u2019s Hospital, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1018-5139","authenticated-orcid":false,"given":"Niccol\u00f2","family":"Bolli","sequence":"additional","affiliation":[{"name":"4Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy"},{"name":"5Hematology Division, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3673-0104","authenticated-orcid":false,"given":"Giada","family":"Bianchi","sequence":"additional","affiliation":[{"name":"2Amyloidosis Program, Brigham and Women\u2019s Hospital, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"6Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"issue":"6","key":"2024070913154269700_bib1","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.hoc.2020.08.001","article-title":"Systemic amyloidosis due to clonal plasma cell diseases","volume":"34","author":"Bianchi","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"2024070913154269700_bib2","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/ajh.26569","article-title":"Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment","volume":"97","author":"Gertz","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"2024070913154269700_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"2024070913154269700_bib4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","article-title":"AL amyloidosis: current chemotherapy and immune therapy treatment strategies: JACC: cardiooncology state-of-the-art review","volume":"3","author":"Bianchi","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"11","key":"2024070913154269700_bib5","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.amjmed.2011.04.013","article-title":"Cardiac amyloidosis: a practical approach to diagnosis and management","volume":"124","author":"Kapoor","year":"2011","journal-title":"Am J Med"},{"issue":"1","key":"2024070913154269700_bib6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/hrt.78.1.74","article-title":"Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes","volume":"78","author":"Dubrey","year":"1997","journal-title":"Heart"},{"issue":"15","key":"2024070913154269700_bib7","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A\u00a0staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2024070913154269700_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"2024070913154269700_bib9","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024070913154269700_bib10","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3324\/haematol.2019.218859","article-title":"Predicting survival in light chain amyloidosis","volume":"104","author":"Palladini","year":"2019","journal-title":"Haematologica"},{"issue":"9","key":"2024070913154269700_bib11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024070913154269700_bib12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2024070913154269700_bib13","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024070913154269700_bib14","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.3324\/haematol.2017.183749","article-title":"Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone","volume":"103","author":"Leung","year":"2018","journal-title":"Haematologica"},{"issue":"Suppl_1","key":"2024070913154269700_bib15","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2019-124206","article-title":"The effect of cytogenetic abnormalities on organ involvement and survival in patients with AL amyloidosis","volume":"134","author":"Ozga","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2024070913154269700_bib16","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cam4.3683","article-title":"AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival","volume":"10","author":"Ozga","year":"2021","journal-title":"Cancer Med"},{"issue":"1","key":"2024070913154269700_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis","volume":"11","author":"Premkumar","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2024070913154269700_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2024070913154269700_bib19","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2024070913154269700_bib20","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024070913154269700_bib21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2017-07-746453","article-title":"Age-related clonal hematopoiesis","volume":"131","author":"Shlush","year":"2018","journal-title":"Blood"},{"issue":"21","key":"2024070913154269700_bib22","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood.2021011320","article-title":"Clinical relevance of clonal hematopoiesis in persons aged \u226580 years","volume":"138","author":"Rossi","year":"2021","journal-title":"Blood"},{"issue":"21","key":"2024070913154269700_bib23","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1182\/bloodadvances.2021006498","article-title":"MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort","volume":"6","author":"Da Vi\u00e0","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2024070913154269700_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024070913154269700_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamacardio.2018.3965","article-title":"Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure","volume":"4","author":"Dorsheimer","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"3","key":"2024070913154269700_bib26","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.121.037388","article-title":"Clonal hematopoiesis is associated with higher risk of stroke","volume":"53","author":"Bhattacharya","year":"2022","journal-title":"Stroke"},{"issue":"20","key":"2024070913154269700_bib27","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.jacc.2023.03.401","article-title":"Clonal hematopoiesis of indeterminate potential predicts adverse outcomes in patients with atherosclerotic cardiovascular disease","volume":"81","author":"Gumuser","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"14","key":"2024070913154269700_bib28","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024070913154269700_bib29","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/bloodadvances.2021004926","article-title":"Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenstr\u00f6m macroglobulinemia","volume":"6","author":"Tahri","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2024070913154269700_bib30","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1182\/bloodadvances.2021006652","article-title":"Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma","volume":"6","author":"Peres","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2024070913154269700_bib31","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1038\/s41467-020-16805-5","article-title":"Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant","volume":"11","author":"Mouhieddine","year":"2020","journal-title":"Nat Commun"},{"issue":"6","key":"2024070913154269700_bib32","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/j.seminoncol.2022.11.001","article-title":"Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias","volume":"49","author":"Testa","year":"2022","journal-title":"Semin Oncol"},{"issue":"7","key":"2024070913154269700_bib33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-022-00706-5","article-title":"Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms","volume":"12","author":"Gagnon","year":"2022","journal-title":"Blood Cancer J"},{"issue":"4","key":"2024070913154269700_bib34","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jmoldx.2016.02.003","article-title":"Validation and implementation of a custom next-generation sequencing clinical assay for hematologic malignancies","volume":"18","author":"Kluk","year":"2016","journal-title":"J\u00a0Mol Diagn"},{"issue":"18","key":"2024070913154269700_bib35","first-page":"2214","article-title":"A\u00a0practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic data sets","volume":"141","author":"Vlasschaert","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2024070913154269700_bib36","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3324\/haematol.2014.113381","article-title":"Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol","volume":"100","author":"Bolli","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"2024070913154269700_bib37","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1182\/blood-2015-11-683334","article-title":"Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies","volume":"128","author":"McKerrell","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2024070913154269700_bib38","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1038\/s41375-020-0896-8","article-title":"Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking","volume":"34","author":"Dawoud","year":"2020","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3427\/2233907\/blooda_adv-2024-012840-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3427\/2233907\/blooda_adv-2024-012840-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T13:16:16Z","timestamp":1720530976000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/13\/3427\/515855\/Clonal-hematopoiesis-of-indeterminate-potential-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":38,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012840","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2024,6,27]]}}}